CXCR4 and leukemia: AMD3100 is a clinically-approved CXCR4 antagonist used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize leukemia and lymphoma cells into the bloodstream where they become vulnerable to cytarabine and anthracycline chemotherapy [21–23].